



UNITED STATES PATENT AND TRADEMARK OFFICE

IFW
UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/779,457	02/13/2004	Martin Kammler	YOR920030623US1 (8728-671)	8968
7590	07/01/2005			EXAMINER NOVACEK, CHRISTY L
Frank Chau, Esq. F. CHAU & ASSOCIATES, LLC Suite 501 1900 Hempstead Turnpike East Meadow, NY 11554			ART UNIT 2822	PAPER NUMBER

DATE MAILED: 07/01/2005

Please find below and/or attached an Office communication concerning this application or proceeding.

RECEIVED
OIF/EPAP

JUL 12 2005

Office Action Summary	Application No.	Applicant(s)
	10/779,457	KAMMLER ET AL.
	Examiner Christy L. Novacek	Art Unit 2822

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --
Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

1) Responsive to communication(s) filed on 13 February 2004.
 2a) This action is FINAL. 2b) This action is non-final.
 3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

4) Claim(s) 1-32 is/are pending in the application.
 4a) Of the above claim(s) _____ is/are withdrawn from consideration.
 5) Claim(s) _____ is/are allowed.
 6) Claim(s) 1-32 is/are rejected.
 7) Claim(s) _____ is/are objected to.
 8) Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

9) The specification is objected to by the Examiner.
 10) The drawing(s) filed on _____ is/are: a) accepted or b) objected to by the Examiner.
 Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
 Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
 11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
 a) All b) Some * c) None of:
 1. Certified copies of the priority documents have been received.
 2. Certified copies of the priority documents have been received in Application No. _____.
 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

1) <input checked="" type="checkbox"/> Notice of References Cited (PTO-892)	4) <input type="checkbox"/> Interview Summary (PTO-413)
2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948)	Paper No(s)/Mail Date. _____
3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08) Paper No(s)/Mail Date _____	5) <input type="checkbox"/> Notice of Informal Patent Application (PTO-152)
	6) <input type="checkbox"/> Other: _____

DETAILED ACTION

This office action is in response to the communication filed February 13, 2004.

Claim Rejections - 35 USC § 102

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless –

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

Claims 1, 2, 8-11, 13-19, 25-27 and 29-32 are rejected under 35 U.S.C. 102(b) as being anticipated by Xie (US 5,888,885).

Regarding claim 1, Xie discloses forming a nucleation site including at least one surface or subsurface defect at a predetermined area of the substrate by implantation with ions and growing a quantum dot on the nucleation site (Fig. 4, 5; col. 2, ln. 40 – col. 3, ln. 25).

Regarding claims 2 and 18, Xie discloses forming the quantum dot on the nucleation site by strained layer epitaxy (col. 3, ln. 5-45).

Regarding claims 8 and 25, Xie discloses annealing the substrate after implantation (col. 2, ln. 49-57).

Regarding claims 9 and 26, Xie discloses that the annealing is performed at a temperature in the range of 500-600°C (col. 2, ln. 55-56).

Regarding claim 10, Xie discloses that the substrate is a silicon substrate (col. 2, ln. 17).

Regarding claim 11, Xie discloses that the step of growing a quantum dot on the nucleation site includes growing a Ge island on the Si substrate by strained layer epitaxy (col. 3, ln. 5-45).

Regarding claims 13 and 29, Xie discloses encapsulating the quantum dot (col. 3, ln. 26-45).

Regarding claims 14 and 30, Xie discloses that the step of encapsulating the quantum dot includes forming an overgrowth layer over the substrate and the quantum dot (col. 3, ln. 26-45).

Regarding claims 15 and 31, Xie discloses patterning the substrate to form at least one prepatterned area (col. 1, ln. 66 – col. 2, ln. 14).

Regarding claims 16 and 32, Xie discloses that the location of the nucleation site is determined based on the prepatterned area (col. 1, ln 66 – col. 2, ln. 14).

Regarding claim 17, Xie discloses forming a nucleation site at a predetermined area of a semiconductor device layer by implantation with ions, the nucleation site including at least one surface or subsurface defect at the predetermined area, and growing a quantum dot on the nucleation site (Fig. 4, 5; col. 2, ln. 40 – col. 3, ln. 25).

Regarding claim 19, Xie discloses that the semiconductor device layer is part of an optoelectronic device (col. 1, ln. 5-16; col. 3, ln. 46-65).

Regarding claim 27, Xie discloses that the substrate is a Si substrate and the step of growing a quantum dot on the nucleation site includes growing a Ge island on the Si substrate by strained layer epitaxy (col. 3, ln. 5-45).

Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person

having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

Claims 3-7 and 20-24 are rejected under 35 U.S.C. 103(a) as being unpatentable over Xie (US 5,888,885) in view of Kato (US 5,532,184).

Regarding claims 3 and 20, Xie discloses implanting ions into the substrate, but does not disclose what method is used to do the implantation. Like Xie, Kato discloses implanting ions into a substrate at predetermined areas to form locations at which quantum dots are to be grown. Kato teaches that these ions can successfully be implanted using a focused ion beam device (col. 4, ln. 54-63). At the time of the invention, it would have been obvious to one of ordinary skill in the art to implant the ions of Xie using a focused ion beam device as taught by Kato because Xie does not disclose any particular implantation method and Kato teaches that a focused ion beam device can successfully be used for the purpose of implanting ions at predetermined areas of a substrate where quantum dots are to be formed.

Regarding claims 4 and 21, Xie, in one embodiment, discloses implanting Ge ions, but Xie does not limit the type of ions that can be implanted. Like Xie, Kato discloses implanting ions into a substrate at predetermined areas to form locations at which quantum dots are to be grown. Kato teaches that these ions can successfully be implanted using gallium or silicon ions (col. 4, ln. 59-61; col. 6, ln. 26-30). At the time of the invention, it would have been obvious to one of ordinary skill in the art to use gallium, silicon or any other non-conductive ions big enough to form defects in the substrate for the implantation disclosed by Xie because Xie does not limit the type of ions that can be implanted and Kato teaches that a variety of ions including gallium and silicon can be successfully used to implant the substrate.

Regarding claims 5, 6, 22 and 23, Xie discloses that if germanium ions are implanted, they are implanted at an energy of 50keV with a dosage of 10^{16} ions/cm² (col. 4, ln. 18-21). Xie does not disclose implanting gallium ions. As discussed above in reference to claims 4 and 21, it would have been obvious to one of ordinary skill in the art to use gallium ions to implant the substrate of Xie as taught by Kato. Kato teaches that the gallium ions can be implanted at a beam energy of 10-300keV, a beam current of 3-500pA, and a dosage of 10^{11} - 10^{15} ions/cm² (col. 6, ln. 45-47). At the time of the invention, it would have been obvious to one of ordinary skill in the art to use routine experimentation to determine an optimal length of exposure time of the implantation process of Xie, depending upon the exact beam energy, current and dosage of ions implanted because such variables of art recognized importance are subject to routine experimentation and discovery of an optimum value for such variables is obvious. See *In re Aller*, 105 USPQ 233 (CCPA 1955).

Regarding claims 7 and 24, Xie discloses that the nucleation site includes a spot formed on the substrate, but does not disclose the diameter of the spot. Like Xie, Kato discloses implanting ions into a substrate at predetermined areas to form locations at which quantum dots are to be grown. Kato teaches that these ions can successfully be implanted using a beam width of 2-50nm wide, with the beam size corresponding to the width of the nucleation site (col. 5, ln. 12-16; col. 6, ln. 45-48). At the time of the invention, it would have been obvious to one of ordinary skill in the art to form the nucleation site of Xie using the beam size and, hence, the nucleation site diameter size, taught by Kato because Xie does not disclose any particular nucleation site diameter and Kato teaches that a nucleation site of 2-50nm wide can successfully nucleate quantum dot growth.

Claims 12 and 28 are rejected under 35 U.S.C. 103(a) as being unpatentable over Xie (US 5,888,885) in view of Fukushima et al. (US 6,351,007).

Regarding claims 12 and 28, Xie discloses forming a Ge island by epitaxial growth at a temperature of 550°C, but Xie does not disclose the Ge precursor gas used, nor the pressure under which the reaction takes place (col. 4, ln. 25-33). Like Xie, Fukushima discloses growing a Ge island by epitaxial growth. Fukushima teaches that the Ge island can be successfully grown by using a precursor of digermane gas at a temperature range of 550-600° at a pressure of 10⁻⁶ torr (col. 6, ln. 2-15; col. 6, ln. 50-60; col. 10, ln. 62 – col. 11, ln. 4; col. 18, ln. 17-29). At the time of the invention, it would have been obvious to one of ordinary skill in the art to use the Ge growing conditions taught by Fukushima to grow the Ge island of Xie because Fukushima teaches that by using this Ge growth method, a Ge quantum structure of the desired size can be uniformly formed with high reproducibility (col. 17, ln. 49 – col. 18, ln. 53).

Conclusion

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Christy L. Novacek whose telephone number is (571) 272-1839. The examiner can normally be reached on Monday-Thursday and alternate Fridays 7:30 - 5:00.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Amir Zarabian can be reached on (571) 272-1852. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

CLN

June 27, 2005



JENNIFER PARAGIAN
TECHNICAL SUPERVISOR
EXAMINER
TECHNICAL SUPERVISOR
CLN

Notice of References Cited		Application/Control No.	Applicant(s)/Patent Under Reexamination KAMMLER ET AL	
		10/779,457	Examiner Christy L. Novacek	
		Art Unit 2822	Page 1 of 1	

U.S. PATENT DOCUMENTS

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Name	Classification
	A	US-6,351,007	02-2002	Fukushima et al.	257/314
	B	US-5,888,885	03-1999	Xie, Ya-Hong	438/493
	C	US-5,532,184	07-1996	Kato, Yoshimine	438/172
	D	US-			
	E	US-			
	F	US-			
	G	US-			
	H	US-			
	I	US-			
	J	US-			
	K	US-			
	L	US-			
	M	US-			

FOREIGN PATENT DOCUMENTS

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Country	Name	Classification
	N					
	O					
	P					
	Q					
	R					
	S					
	T					

NON-PATENT DOCUMENTS

*		Include as applicable: Author, Title Date, Publisher, Edition or Volume, Pertinent Pages)
	U	
	V	
	W	
	X	

*A copy of this reference is not being furnished with this Office action. (See MPEP § 707.05(a).)
Dates in MM-YYYY format are publication dates. Classifications may be US or foreign.

BEST AVAILABLE COPY

TC2800

三

Organization U. S. DEPARTMENT OF COMMERCE Bldg. U. S. DEPARTMENT OF COMMERCE
Commissioner for Patients
PO. BOX 1450 ALEXANDRIA, VA 22313-1450
IF UNDELIVERABLE RETURN IN THIS ENVELOPE

AN EQUAL OPPORTUNITY EMPLOYER

CHAY GOU

RECEIVERS

JUL 11 2005

USPTO MAIL CENTER

CHAU900* 115542083 1704 16 07/07/05
FORWARD TIME EXP RTN TO SEND
:P. CHAU & ASSOCIATES LLC
130 WOODBURY RD
WOODBURY NY 11797-1409

RETURN TO SENDER